Milliner Platform

Categories

Description

A platform that designs safer, more effective antibody therapies using machine learning and synthetic biology.

Summary

BigHat Biosciences' Milliner platform combines synthetic biology with advanced machine learning technologies to accelerate the discovery and engineering of antibody therapies. It allows for the rapid synthesis, purification, and characterization of hundreds of recombinant antibodies, targeting diseases with high unmet needs such as infections and cancers. This integration aims to produce next-generation therapies with improved safety and efficacy through rational molecular design.

Use Cases

• Accelerating the discovery of antibody therapies for challenging diseases like cancer.
• Rapidly synthesizing and testing antibodies for infections to identify candidates with the best therapeutic potential.